Published online May 6, 2014. doi: 10.5315/wjh.v3.i2.29
Revised: January 27, 2014
Accepted: March 17, 2014
Published online: May 6, 2014
Core tip: Anti-CD20 monoclonal antibodies are widely used for the treatment of hematological malignancies and autoimmune disorders. These agents produce prolonged B-cell depletion and significant immune suppression. In this review, we summarized the clinical use of anti-CD20 monoclonal antibodies and the reports of acute or chronic hepatitis associated with the use of these agents. Most of these hepatitis cases had viral etiologies. We discuss the mechanisms of the hepatitis caused by these drugs. These infections not only interrupted the immunotherapy but are also associated with high mortality and morbidity. This review may prompt physicians to monitor patients’ liver function more closely and to provide adequate prophylaxis while using these agents.